Week in review: Corneal shield, Novartis acquisition, preloaded IOL
- Posted on: Nov 6 2020
- Leave a response
This week, research hints that the cornea may have resistance against SARS-CoV-2, Novartis invests in a novel optogenetic gene therapy technology, and Bausch + Lomb launches a preloaded toric IOL.
Source: AAO
Posted in: Uncategorized
